Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | Next revision Both sides next revision | ||
|
publications [2024/02/13 16:00] ramirez [2024] |
publications [2024/04/13 17:25] ramirez [2024] |
||
|---|---|---|---|
| Line 2: | Line 2: | ||
| ===== 2024 ===== | ===== 2024 ===== | ||
| + | Xie O, Morris JM, Hayes AJ, Towers RJ, Jespersen MG, Lees JA, Ben Zakour NL, Berking O, Baines SL, Carter GP, Tonkin-Hill G, Schrieber L, McIntyre L, Lacey JA, James TB, Sriprakash KS, Beatson SA, Hasegawa T, Giffard P, Steer AC, Batzloff MR, Beall BW, Pinho MD, Ramirez M, Bessen DE, Dougan G, Bentley SD, Walker MJ, Currie BJ, Tong SYC, McMillan DJ, Davies MR. 2024. Inter-species gene flow drives ongoing evolution of Streptococcus pyogenes and //Streptococcus dysgalactiae// subsp. //equisimilis//. Nat Commun 15:2286. | ||
| + | |||
| Mendes Pedro D, Paulo SE, Santos CM, Fonseca AB, [[people:jmelocristino|Melo-Cristino J]], Pereira AA, Caneiras C. 2024. <fc #0000FF>Extensively drug-resistant //Pseudomonas aeruginosa//: clinical features and treatment with ceftazidime/avibactam and ceftolozane/tazobactam in a tertiary care university hospital center in Portugal – A cross-sectional and retrospective observational study</fc>. Frontiers in Microbiology 15. //In press// | Mendes Pedro D, Paulo SE, Santos CM, Fonseca AB, [[people:jmelocristino|Melo-Cristino J]], Pereira AA, Caneiras C. 2024. <fc #0000FF>Extensively drug-resistant //Pseudomonas aeruginosa//: clinical features and treatment with ceftazidime/avibactam and ceftolozane/tazobactam in a tertiary care university hospital center in Portugal – A cross-sectional and retrospective observational study</fc>. Frontiers in Microbiology 15. //In press// | ||